An Analysis Of RedHill Biopharma Ltd. (RDHL)’s Weekly Performance


As of Friday close, RedHill Biopharma Ltd.’s (NASDAQ:RDHL) stock was down -$0.04, moving down -24.28 percent to $0.14. The average number of shares traded per day over the past five days has been 3,468,920 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0616 fall in that time frame. In the last twenty days, the average volume was 2,909,310, while in the previous 50 days, it was 6,706,110.

Since last month, RDHL stock retreated -36.31%. Shares of the company fell to $0.1350 on 03/17/23, the lowest level in the past month. A 52-week high of $3.27 was reached on 01/27/23 after having rallying from a 52-week low of $0.13. Since the beginning of this year, RDHL’s stock price has dropped by -2.85% or -$0.0040, and marked a new high 3 times. However, the stock has declined by -95.83% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Financial Health

In the three months ended June 29, RedHill Biopharma Ltd.’s quick ratio stood at 0.40, while its current ratio was 0.40, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 50.50% percent. In the year ended June 29, operating margins totaled -75.40%. Based on annual data, RDHL earned $36.35 million in gross profit and brought in $85.76 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -83.90%. Return on equity (ROE) for the past 12 months was 679.60%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RDHL’s revenue rose 24.95% during the quarter, while net income inched up to $85.76 million. While analysts expected RedHill Biopharma Ltd. to report -$0.03 quarterly earnings, the actual figure was -$0.2 per share, beating the consensus estimate by -566.70%. During the quarter, the company generated -$5.02 million in EBITDA. The liabilities of RedHill Biopharma Ltd. were 203.22 million at the end of its most recent quarter ended June 29, and its total debt was $120.83 million.

Technical Picture

This quick technical analysis looks at RedHill Biopharma Ltd.’s (RDHL) price momentum. With a historical volatility rate of 125.22%, the RSI 9-day stood at 10.70% on 17 March.

With respect to its five-day moving average, the current RedHill Biopharma Ltd. price is down by -31.13% percent or -$0.0616. At present, RDHL shares trade -39.96% below its 20-day simple moving average and -75.62% percent below its 100-day simple moving average. However, the stock is currently trading approximately -15.13% below its SMA50 and -87.83% below its SMA200.

Stochastic coefficient K was 12.63% and Stochastic coefficient D was 16.60%, while ATR was 0.0208. Given the Stochastic reading of 1.19% for the 14-day period, the RSI (14) reading has been calculated as 19.89%. As of today, the MACD Oscillator reading stands at -0.0222, while the 14-day reading stands at -0.0359.

Analyst Ratings

Cantor Fitzgerald launched its rating on RedHill Biopharma Ltd. (NASDAQ: RDHL) to an Overweight in a note to investors on August 31, 2021. RedHill Biopharma Ltd. (RDHL) has been rated Buy by analysts. According to 0 brokerage firms, RDHL is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate RedHill Biopharma Ltd. stock as buy, with 1 recommending it as overweight.

With a median target price of $1.00, the current consensus forecast for the stock is $1.00 – $1.00. Based on these forecasts, analysts predict RedHill Biopharma Ltd. (RDHL) will achieve an average price target of $1.00.


Please enter your comment!
Please enter your name here